Allergic Diseases and Asthma in Pregnancy
Updated: January 2016
Posted: March 2009
Isabella Pali-Schöll, PhDa, Jennifer Namazy, MDb, and Erika Jensen-Jarolim, MDa
aThe interuniversity Messerli Research Institute, c/o Department of Pathophysiology and Allergy Research, Center of Physiology, Pathophysiology and Immunology, Medical University of Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria.
bScripps Clinic 7565 Mission Valley Rd Ste 200, San Diego, CA 92108 USA.
Isabella Pali-Schöll, PhD, Department of Comparative Medicine, the interuniversity Messerli Research Institute, c/o Dept. of Pathophysiology and Allergy Research, Center of Pathophysiology, Infectiology and Immunology, Medical University Vienna, Währinger Gürtel 18-20, 1090 Vienna, Austria; e-mail: email@example.com
Key words: allergy, atopy, newborn, pregnancy, prevention
This work was supported by the Austrian Science Fund (FWF) project SFB F4606-B19.
This synopsis is based on a review that is submitted to WAO journal.
|PUFA||polyunsaturated fatty acids|
|PUPPP||pruritic urticarial papules and plaques of pregnancy|
|Th2||T helper type 2|
In the United States of America (USA), about 18-30% of women in the childbearing age suffer from allergic diseases, and around 20% of pregnant women are affected by allergies, especially rhinitis and asthma. These two conditions often are present in the same patient (reviewed in ). Other medical conditions that often complicate pregnancy include allergic conjunctivitis, acute urticaria, anaphylaxis, food allergy and drug allergy. Optimal management of these disorders during pregnancy is vital to ensure the welfare of the mother and the baby.
The diagnosis of allergy in pregnant women should focus on a detailed medical history and symptom analysis. For diagnosis, (i) a diary of allergy symptoms and (ii) avoidance of suspected allergens accompanied by monitoring of changes of allergic symptoms may be helpful. It has to be emphasized that it is important not to put the mother on a rigid elimination diet for diagnosis of food allergy, as this could negatively influence the nutritional status of both the mother and the growing infant.
In vitro diagnostic tools such as serologic tests for allergen-specific IgE, e.g. CAP or radioallergosorbent test (RAST), or the lymphocyte transformation test for type IV allergy diagnosis are preferred to skin and provocation tests, which should be postponed until after birth because of possible, though rare, anaphylactic reactions.  The same applies to food and other challenge tests. Despite the fact that there are no harmful effects of patch testing during pregnancy or lactation known, most physicians deter testing as general precaution. (http://www.escd.org/education/guidelines/Guidelineversion6_afterIRW_150211final.pdf; accessed 4 January 2016). The attending physician also should bear in mind that some symptoms might be a direct result of pregnancy and not allergy-related, e.g. nasal congestion by vasomotor rhinitis.
Mothers with allergy should avoid exposure to, consumption of and contact with diagnosed specific allergens. Patients should also especially avoid the inhalation of any potent triggers for asthma, such as animal dander, house dust, tobacco smoke and irritating pollutants.
Allergen immunotherapy (AIT, SIT, SLIT should ideally not be initiated during pregnancy because of the risk of systemic reactions. However, the initiation of immunotherapy can be considered in pregnant patients for clinical high-risk indication like anaphylaxis caused by Hymenoptera (insect venom) hypersensitivity. For patients who were already on immunotherapy prior to the pregnancy, maintenance treatment may be continued safely during pregnancy. The allergen dose should not be increased during pregnancy. If pregnancy occurs while the patient is in the build-up phase of immunotherapy and on a low dose, which probably is not therapeutic, immunotherapy could also be discontinued. 
Newer studies indicate that allergen immunotherapy is not only improving the disease in the pregnant patient, but that this treatment might also prevent allergic sensitization in the child. However, more studies are needed to confirm the effect of allergen immunotherapy during pregnancy on the development of sensitization in the child.
The ideal situation during pregnancy is "no pharmacologic therapy", especially during the first trimester. However, in practice, medications must be considered for pregnant patients with medical disorders, based on a thorough appreciation of the potential deleterious effects of untreated disease in the mother, and also potential harm for the unborn.  For instance, women suffering from asthma require drug therapy during pregnancy to prevent life threatening episodes to the mother, which consequently threaten the fetus and have been associated with preterm birth and lower birth weight.
Most of the existing data regarding asthma and allergy medications during pregnancy have not demonstrated adverse effects (Table 1), even though in infants of corticosteroid-treated mothers an increased risk of oral clefts, preeclampsia, preterm birth, and lower birth weight have been reported. Many of the case controls, which showed the association between oral corticosteroid and oral clefts did not provide information on dose, duration or indication. Other studies, which have demonstrated association with OCS and preterm delivery and low birth weight, have been linked with higher doses for longer periods. For example in Bracken’s study, which showed an association with OCS use and preeclampsia, the subjects were on OCS for the duration of pregnancy. However, the potential side effects of any drug must be balanced against the risks to the mother or the infant of suffering from inadequately treated disease.
Table 1. Recommendations for treatment of asthma and allergies in pregnancy
Common asthma medications and safety data
|Inhaled bronchodilators (e.g. Albuterol, Formoterol and Salmeterol)||Human data generally reassuring for short acting and long-acting bronchodilators|
|Theophylline||Reassuring human data; serum levels must be monitored to avoid toxicity|
|Systemic corticosteroids||Human data from smaller case control studies show increase in oral clefts. Larger prospective studies show increase in low birth weight, preterm birth, preeclampsia and intrauterine growth retardation.|
|Inhaled corticosteroids||Human data mainly reassuring. There may be an increased risk of malformations seen with higher doses.|
|Leukotriene Receptor Antagonist (e.g. Montelukast, Zafirlukast)||Human data are generally reassuring|
|5-Lipoxygenase-Inhibitor||Generally avoided during pregnancy due to the available less reassuring animal data.|
|Omalizumab||Increased risk of low birth weight and preterm birth; likely severity of asthma may confound to these observations.|
Common allergic rhinitis medications and safety data
|Oral antihistamines (e.g. Azelastine, Cetirizine, Chlorpheniramine, Dexchlorpheniramine, Fexofenadine, Diphenhydramine, Hydroxyzine, Loratadine)||Human data are generally reassuring.
Hydroxyzine should be used cautiously during first trimester based on animal data. Fexofenadine (an active metabolite of Terfenedine): no reports of increased congenital malformations, however, no epidemiologic studies in human pregnancy available.
|Oral and Nasal Decongestants (e.g. Oxymetazoline, Phenylephrine, Phenylpropanolamine, Pseudoephedrine)||Oxymetazoline has been associated with possible uteroplacental insufficiency at higher doses. Phenylephrine has been associated with clubfoot and eye/ear malformations. Phenylpropanolamine associated with congenital malformations, gastroschisis and ventricular septal defect. Pseudoephedrine associated with gastroschisis, hemifacial microsomia and small intestinal atresia in some case-control studies.|
|Intranasal Antihistamines (e.g. Azelastine, Olapatadine)||Animal studies are reassuring.|
|Intranasal Corticosteroids (e.g. Budesonide, Fluticasone, Triamcinolone, Mometasone)||Substantial reassuring data for inhaled corticosteroids. Risk of increased malformations at high dose, but severity of allergic rhinitis may be a confounding factor for these outcomes.|
FDA categorization by letters has been removed for labeling of drugs used during pregnancy and lactation. New FDA regulations for labeling of mediations are available at http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/Labeling/ucm093307.htm (accessed 4 January 2016).
Treatment of asthma 
Certain physiological changes occur normally during pregnancy, like increased tidal volume and minute ventilation, and decreased residual volume, functional residual capacity and diffusion capacity. These alterations are primarily the result of hormonal effects. The physiologically elevated position of the diaphragm and hyperventilation occurring in pregnancy further increase the risk of hypoxia. Preexisting asthma symptoms may worsen, improve, or remain unchanged during pregnancy. Each of these three possibilities is observed in about one third of cases. Optimal asthma treatment is crucial, as the risk of pre-eclampsia, premature birth, low birth weight, and maternal and neonatal hypoxia and morbidity posed by undertreated asthma may be greater than that from the use of oral steroids for the treatment of asthma.
Treatment of acute asthma is similar to that recommended for non-pregnant patients including inhaled beta2 agonists, oxygen (essential), and corticosteroids (oral or parenteral). It is also wise to add nebulized ipratropium bromide in patients who do not respond to beta2 agonists. Intravenous aminophylline is not generally recommended in the emergency management of acute asthma (because of its potentially harmful effects) but may be used in pregnant patients hospitalized for acute asthma (theophylline levels should be monitored). Intravenous magnesium sulfate may be beneficial in acute severe asthma as an adjunct to inhaled beta2 agonists and corticosteroids.
The goals of management of chronic asthma are the same as those for asthma in general, including prevention of severe exacerbations, improvement of quality of life (no interference with sleep or daily activities) and maintenance of normal lung function. The recommendations for medical treatment have been summarized by the Global Initiative for Asthma (GINA) working group including management of asthma during pregnancy (Global strategy for asthma management and prevention. Updated 2015. http://www.ginasthma.org/local/uploads/files/GINA_Report_2015_Aug11.pdf. Accessed 4 January 2016). A step-wise approach is suggested for medical treatment. Inhaled salbutamol is the preferred short-acting beta-agonist, with an outstanding safety profile, and among inhaled corticosteroids budesonide is preferred based on the available data. Salmeterol is the preferred agent when long-acting beta2 agonists are indicated in a pregnant woman as add-on treatment for persistent asthma. Leukotriene modifiers may be used as alternative add-on treatment: montelukast and zafirlukast are the preferred anti-leukotriene drugs. Zileuton in contrast, being the only leukotriene synthesis inhibitor, is not recommended in pregnancy due to its potential to cause abnormal liver function (FDA pregnancy category C).
Patients whose asthma is not controlled with maximal doses of bronchodilators and anti-inflammatory agents may need systemic corticosteroids. The lowest possible effective dose should be used. Patients must be monitored closely for potential adverse effects of corticosteroids, especially gestational diabetes, preeclampsia, and intrauterine growth retardation. Based on the available data, control of maternal asthma is essential to reduce the risk of perinatal complications. As pregnant women are hesitant about continuing asthma medications during pregnancy, asthma education is a critical component in the management of the pregnant asthmatic patient.
One of the treatment options for moderate to severe persistent allergic asthma is the recombinant DNA-derived humanized IgG1k monoclonal antibody omalizumab (Xolair®), which specifically binds to free human immunoglobulin E (IgE) in the blood. It currently has an FDA Category B classification based on reassuring animal studies and the expected limited placental passage in the first trimester due to the size of the molecule. We have established an ongoing registry with a target goal of enrolling 250 asthmatic women treated with omalizumab during pregnancy. 
Significant nasal symptoms occur in approximately 30% of pregnant women. Pregnancy-associated hormones have direct and indirect effects on nasal blood flow and mucous glands. The most common causes of nasal symptoms necessitating treatment during pregnancy are allergic rhinitis, rhinitis medicamentosa, sinusitis, and (non-allergic) vasomotor rhinitis. "Vasomotor rhinitis of pregnancy" is a syndrome of nasal congestion and vasomotor instability limited to the gestational period. Allergic rhinitis commonly co-exists with asthma. As with asthma, pre-existing allergic rhinitis can worsen, improve, or remain unchanged during pregnancy.
The general principles of treatment for pregnant women with asthma and allergic rhinitis do not differ from the step-wise approach recommended for treatment of non-pregnant women. The initial treatment steps are non-pharmacological and shall include avoidance of allergens and irritants, furthermore, nasal lavages with salty water solutions. The mainstays of pharmacological therapy for allergic rhinitis in non-pregnant as well as pregnant patients are antihistamines and intranasal glucocorticoids. No important differences in efficacy or safety appear to exist between the various intranasal glucocorticoid preparations.. Most pregnant women who require antihistamines for allergic rhinitis are appropriately treated with a second generation agent, because these drugs are less sedating and have fewer cholinergic side effects compared with first generation agents. Among second generation antihistamines, loratadine (10 mg once daily) and cetirizine (10 mg once daily) may be considered the second generation antihistamines of choice in pregnancy.
For decongestant treatment, there are insufficient safety data. The narrowing of blood vessel due to this medication could have negative effects on the fetus, and furthermore, decongestant nasal sprays can cause addition. These medications should therefore be avoided during pregnancy.
Treatment of anaphylaxis 
The management of anaphylaxis during pregnancy is similar to treatment of non-pregnant patients. The first step is to remove the trigger of the anaphylactic reaction. Of the routine anti-anaphylaxis medications, epinephrine (adrenaline) should be promptly injected i.m. Adequate intravascular volume repletion and oxygenation are particularly important in the management of anaphylaxis during pregnancy to prevent both maternal and fetal complications. The pregnant hypotensive patient should be placed on her left side to prevent additional positional hypotension resulting from compression of the vena cava inferior by the gravid uterus, with her lower extremities elevated. Intravenous epinephrine may be required, despite its potential to cause decreased uteroplacental blood flow. Glucocorticoids should be administered early to patients with severe anaphylaxis. For laryngeal spasm, intubation and in rare cases tracheotomy may be necessary.
Treatment of atopic eczema/dermatitis 
Gestational itchy dermatoses are relatively common, with eczema being diagnosed in 36% to 49% of all pregnancy dermatoses. Treatment of atopic dermatitis during pregnancy should emphasize avoidance of triggering factors and reliance on topical treatment with emollients to nourish and re-establish the skin barrier. Topical corticosteroids are prescription-dependent first-line treatment, however, they should only be initiated when clinically indicated with the least potent effective preparations. Oral antihistamines (AH) may be required as systemic treatment. Short-term use of (sedating) first-generation antihistamines may be beneficial in the setting of sleep loss secondary to itch. Chlorpheniramine and diphenhydramine are considered safe during the first trimester. However, also second-generation drugs are generally safe, and loratidine is the preferred second-generation antihistamine in pregnancy (reviewed in ). In general, AH should be used cautiously in the last month of pregnancy, because of possible withdrawal symptoms in the child, like poor feeding, diarrhea, irritability, or tremulousness, which can last up to 4 weeks after birth. [12, 13] Atopic dermatitis can additionally be managed with UV phototherapy (UVA, broadband UVA and UVB, or narrowband UVB).
Treatment of urticaria and angioedema 
The pattern and causes of urticaria and angioedema in pregnancy are similar to those in non-pregnant patients. A unique form of urticaria associated with pregnancy ("pregnancy urticaria", Pruritic urticarial papules and plaques of pregnancy PUPPP) mainly occurs in primigravida mothers in the last trimester.[15, 16] The first step in treatment of urticaria and angioedema in pregnancy is identification and avoidance of causative factors. Antihistamines should be avoided if possible, but if required, the lowest dose of chlorpheniramine, loratadine, or cetirizine may be used.
The causes of allergy in general and of specific sensitization in newborns in particular have not been completely determined yet. Besides the role of genetic predisposition, some factors have been identified that may either contribute to sensitization of the mother and to the subsequent transfer of a predisposition for allergy to the offspring, or that directly induce sensitization in the offspring, that manifests shortly after birth or at a young age (reviewed in ).
Family history of atopy/allergy
The degree of risk for atopy/allergy appears to be directly related to the family history of allergy and especially to maternal atopy. If neither parent is allergic, the chance for allergies in the child is about 5-16%. If one parent is allergic, the risk increases to 20-40% (father: 33%, mother: 45%), and if both are allergic, the risk is greater than 40-60% (if patients have the same allergy: 50-80%), especially for developing the same organ-specific symptoms.
Exposure to tobacco smoke
In a recent human study performed by parental questionnaires, exposure to smoke in utero or during infancy enhanced the risk for asthma and rhinitis primarily in early childhood, and the risk for eczema at later ages of the children. In human blood samples, Th2 cytokines responsible for a predisposition toward allergy were elevated in the neonates only of mothers who had smoked during pregnancy. In addition, total and specific IgE levels, total eosinophil counts, incidence of airway disease and positive results on skin prick tests were also increased in children who were exposed to smoke either during pregnancy or in early childhood.
Maternal diet 
Recent research has focused on the role of several essential nutrients in the diet of the mother, like Vitamin D, zinc, folate and n-3 polyunsaturated fatty acids (PUFAs). Contrasting data exist on the effects of n-3 PUFA. On the one hand, a diet higher in n-6 polyunsaturated fatty acids (PUFAs) -as present, for example, in margarine and vegetable oils- seems to be more likely to induce eczema than n-3 PUFAs, which are found in fish. Accordingly, several observational studies show that a high intake of fish and oily fish during pregnancy results in a reduced incidence of allergy in the children (reviewed in ). On the other hand, a recent Cochrane systematic review revealed no evidence for supplementation of the mother with n-3 PUFA during pregnancy and lactation for prevention of allergy in the child.
Current evidence suggests a protective effect of maternal intake of vitamin D, vitamin E, or zinc for wheezing in childhood, but the data are not conclusive for an effect on asthma or other atopic conditions.
The effect of folate and folic acid supplementation is intensively discussed. Higher levels in maternal blood seem to be positively associated with atopic dermatitis in the offspring. Controversially, recent studies and a systematic review found no association of prenatal folic acid supplementation and atopic diseases in children.[28, 29]
Regarding allergenic food consumption during pregnancy and lactation, there has been extensive reviewing of data. According to the updated directive (No. 1169/2011, entered into application on 13 December 2014) of the Commission of European Communities, the 14 most allergenic foods have to be labeled on pre-packed food, and this declaration/information has also to be provided for non-pre-packed food. These allergen sources are crustaceans, mollusks, fish, nuts, milk, egg, cereals containing gluten, peanuts, soybeans, sesame, mustard, celery, lupines, and the products of all these, as well as sulphur dioxide and sulphites
Some studies suggest that allergen exposure during pregnancy, lactation and early childhood may be necessary to induce tolerance. Accordingly, avoidance of allergenic food by the mother, e.g. milk, egg and nuts during pregnancy, did not appear to lower the risk of sensitization in the child. Moreover, a balanced diet prevents malnutrition of both mother and child.
Use of anti-acid medication
Changes of hormone levels during pregnancy and the growing volume of the fetus often lead to heartburn, reflux and abdominal pain in the mother. About 70% of pregnant women are affected by these symptoms during their last trimester and 50% of them are likely to take acid-suppressing medication. However, animal and human studies indicate that acid suppression and the resulting elevated pH in the stomach may lead to an increased risk of sensitization to food ([32, 33], reviewed in ) and drugs [35, 36]. This mechanism was recently also shown to be true for children aged 0-18 years with gastro-esophageal reflux disease, who were treated with gastric acid suppression medication. Importantly, a sensitization of the mother induced by acid-suppression was shown to lead to an increased risk of food allergy in the newborn in a BALB/c mouse model.  Also in a database-link study of human patients, the positive correlation between acid suppression during pregnancy and increased risk for asthma in children was shown.  For these reasons, pregnancy-associated reflux should most probably be treated by non-pharmacological measures first (avoidance of large meals, sleeping with elevated upper body, not lying down after a meal, avoiding sweet and fatty food as well as alcohol and smoking). In general, during pregnancy and lactation, patients should avoid intake of any medication including non-prescription over-the-counter substances, unless recommended by a physician.
Reduced breastfeeding and early introduction of solid food have been discussed as confounders to allergy development. However, a systematic review of several studies found no clear negative association between early solid food introduction and the development of asthma, food allergy, allergic rhinitis, or animal dander allergy. In addition, there is no effect of allergen-free infants-diet for the primary prevention of allergic diseases. The early introduction of antigens –including potential allergens- in the diet of the child may even be preventive for induction of allergic diseases  (see also section of “Preventive Measures for Mother and Child” below).
Prematurity and low birth weight
Prematurity and low birth weight are not associated with an increased risk for development of food allergy in childhood. The impact of these factors for sensitization to other allergens, such as aeroallergens, has not been investigated. However, one study showed that adolescents who had been born extremely premature (<28 weeks, <1000g) had a substantially decreased expiratory volume and increased bronchial hyperresponsiveness, making them potential candidates for developing asthma. 
Insufficient exposure to environmental bacteria
The "hygiene hypothesis" states that low exposure of the mother during pregnancy and of the newborn in early life to environmental bacteria contributes to a Th2-biased immune response. This hypothesis has been confirmed by several experimental animal and epidemiological human studies, whereas details about the mechanism are still under investigation. 
Cohabitation with pets
In a recent longitudinal study the effects of ownership of a wide range of pets from pregnancy to 7 years of age were investigated. Whereas cat ownership was associated with lower, rabbit and rodent ownership was associated with a higher risk of wheezing. In that study, dog ownership in pregnancy was associated with wheezing in the newborn at the age of 6 months. However, in studies on urban children, especially dog exposure was a clear protective factor against asthma and allergic diseases, at least in children without family predisposition for allergies. Dogs also seem to protect from atopic eczema.[45, 46] The discussion is, however, ongoing. For instance, recent recommendations for the prevention of food allergy and atopic eczema again contained the recommendation to avoid pets during gestation. It is anticipated that an exchange of immunomodulatory allergens such as lipocalins takes place between pets and humans. Reptiles and exotic pets were so far not investigated in any birth cohort studies, but potent allergens may be expected from their feeding animals.
Several studies indicate that cesarean section increases the risk for allergic diseases in children –especially with atopic background- by the lack of contact with maternal vaginal fluid and stool, and therefore reduced exposure to favorable microbes. However, a recent review shows controversial results for the correlation between mode of delivery and the risk for atopic eczema/dermatitis syndrome, allergic rhinitis and allergic asthma in children, and there are also conflicting data on the influence of atopic or allergic parents and CS on the outcome of atopy/allergy in children (reviewed in ). Further prospective studies are needed to elucidate a possible association of mode of delivery and atopy in children.
Preventive Measures for Mother and Child
Primary prevention addresses fetuses during pregnancy as well as symptom-free children at risk (i.e. without the established disease). Children at risk are defined to have one or more allergic parent or sibling.
Based on currently available evidence, guidelines for primary prevention of allergic diseases can be summarized as follows: [51-53]
- Diet of the mother:
no necessity for a special allergen-free diet for the mother during pregnancy and lactation, unless the mother or child has a diagnosed food sensitization.
- Breastfeeding/infant formula:
Infants should be exclusively breastfed for at least 4 months (16 weeks of age) but no longer than 9 months. If not breastfed, special hypoallergenic formula (extensively hydrolyzed, not soy-based) should only be used for high-risk children.
- Diet of the child/complementary feeding (reviewed in , including also a general advice for complementary food introduction):
Complementary feeding can be started (acc. to development and interest of child) between the age of 17 and 26 weeks, optimally in parallel to breastfeeding.
There is no preventive effect of an allergen-free diet for the child during complementary feeding, even for high-risk children:
- fish can be introduced during the first year of life (before the age of 9 months)
- gluten can be introduced between 5th and 7th month of age, optimally in parallel to breastfeeding
- cow’s milk can also be introduced during first year of life, starting with small amounts after an age of 4 months
- egg introduction in small amounts in the form of baked goods at age 4-6 months may be beneficial
- peanut (and tree nut) in the form of butter can first be given between the age of 6-12 months
- no studies report on the detailed effect of soy and shellfish, but also these food groups should be safe when introduced at an early age
- Overweight and obesity shall be avoided to prevent asthma.
- Allergen contact:
- Pets: In case parents wish to acquire a new pet, and if pets are not already living with the family during the pregnancy, a dog rather than a bird, cat, rabbits or rodents should be introduced into the household after the baby’s birth. This is especially relevant in a family at enhanced allergy risk.
- House dust mite:
Measures to reduce house dust mite allergen exposure are not effective for primary prevention, but for reduction of symptoms in already sensitized persons.
- Enzyme allergens: House dust mite- and industrial enzymes reduce the skin barrier function. Their load should be reduced by thorough washing, drying and/or ironing of textiles.
- Indoor pollutants (new furniture, substances from renovations, wall paintings etc.) should be avoided or minimized.
- Indoor climate conditions fostering the growth of fungi should be avoided.
- Immunizations should be performed according to the recommendations of the Standing Committee on Immunization (STIKO) http://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2015/Ausgaben/34_15.pdf?__blob=publicationFile (Accessed 4 January 2016).
For more information on primary, secondary and tertiary prevention of allergy, readers are referred to the document, "Prevention of Allergy and Allergic Asthma," a document based on findings presented at the World Health Organization/World Allergy Organization meeting in January 2002, with the following update from 2014: Schäfer T et al: S3-Leitlinie Allergieprävention –Update 2014 (article in German: http://www.awmf.org/uploads/tx_szleitlinien/061-016l_S3_Allergieprävention_2014-07.pdf. Accessed 4 January 2016). This document also includes a summary of evidence-based guidelines and strength of recommendations.
1. Bousquet J, Schunemann HJ, Samolinski B, Demoly P, Baena-Cagnani CE, Bachert C et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. The Journal of allergy and clinical immunology. 2012;130(5):1049-62. doi:10.1016/j.jaci.2012.07.053.xxxx
2. Simons FE, Schatz M. Anaphylaxis during pregnancy. The Journal of allergy and clinical immunology. 2012;130(3):597-606. doi:10.1016/j.jaci.2012.06.035.
3. Cox L, Nelson H, Lockey R, Calabria C, Chacko T, Finegold I et al. Allergen immunotherapy: a practice parameter third update. The Journal of allergy and clinical immunology. 2011;127(1 Suppl):S1-55. doi:10.1016/j.jaci.2010.09.034.
4. Lieberman J. Should we encourage allergen immunotherapy during pregnancy? Expert review of clinical immunology. 2014;10(3):317-9. doi:10.1586/1744666X.2014.881718.
5. Namazy JA, Schatz M. Pharmacotherapy options to treat asthma during pregnancy. Expert opinion on pharmacotherapy. 2015;16(12):1783-91. doi:10.1517/14656566.2015.1066332.
6. Triche EW, Saftlas AF, Belanger K, Leaderer BP, Bracken MB. Association of asthma diagnosis, severity, symptoms, and treatment with risk of preeclampsia. Obstetrics and gynecology. 2004;104(3):585-93. doi:10.1097/01.AOG.0000136481.05983.91.
7. Namazy J, Cabana MD, Scheuerle AE, Thorp JM, Jr., Chen H, Carrigan G et al. The Xolair Pregnancy Registry (EXPECT): the safety of omalizumab use during pregnancy. The Journal of allergy and clinical immunology. 2015;135(2):407-12. doi:10.1016/j.jaci.2014.08.025.
8. Namazy JA, Schatz M. Asthma and rhinitis during pregnancy. The Mount Sinai journal of medicine, New York. 2011;78(5):661-70. doi:10.1002/msj.20284.
9. Odedra KM. Treatment of rhinitis in pregnancy. Nurs Stand. 2014;29(8):37-41. doi:10.7748/ns.29.8.37.e9089.
10. Babalola O, Strober BE. Treatment of atopic dermatitis in pregnancy. Dermatologic therapy. 2013;26(4):293-301. doi:10.1111/dth.12074.
11. Sidbury R, Davis DM, Cohen DE, Cordoro KM, Berger TG, Bergman JN et al. Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents. Journal of the American Academy of Dermatology. 2014;71(2):327-49. doi:10.1016/j.jaad.2014.03.030.
12. Lione A, Scialli AR. The developmental toxicity of the H1 histamine antagonists. Reprod Toxicol. 1996;10(4):247-55.
13. Serreau R, Komiha M, Blanc F, Guillot F, Jacqz-Aigrain E. Neonatal seizures associated with maternal hydroxyzine hydrochloride in late pregnancy. Reprod Toxicol. 2005;20(4):573-4. doi:10.1016/j.reprotox.2005.03.005.
14. Powell RJ, Leech SC, Till S, Huber PA, Nasser SM, Clark AT. BSACI guideline for the management of chronic urticaria and angioedema. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015;45(3):547-65. doi:10.1111/cea.12494.
15. Matz H, Orion E, Wolf R. Pruritic urticarial papules and plaques of pregnancy: polymorphic eruption of pregnancy (PUPPP). Clinics in dermatology. 2006;24(2):105-8. doi:10.1016/j.clindermatol.2005.10.010.
16. Ghazeeri G, Kibbi AG, Abbas O. Pruritic urticarial papules and plaques of pregnancy: epidemiological, clinical, and histopathological study of 18 cases from Lebanon. International journal of dermatology. 2012;51(9):1047-53. doi:10.1111/j.1365-4632.2011.05203.x.
17. Pali-Scholl I, Renz H, Jensen-Jarolim E. Update on allergies in pregnancy, lactation, and early childhood. The Journal of allergy and clinical immunology. 2009;123(5):1012-21. doi:10.1016/j.jaci.2009.01.045.
18. Cantani A. Pediatric Allergy, Asthma, and Immunology. Springer, Berlin; 2008.
19. Thacher JD, Gruzieva O, Pershagen G, Neuman A, Wickman M, Kull I et al. Pre- and postnatal exposure to parental smoking and allergic disease through adolescence. Pediatrics. 2014;134(3):428-34. doi:10.1542/peds.2014-0427.
20. Noakes PS, Holt PG, Prescott SL. Maternal smoking in pregnancy alters neonatal cytokine responses. Allergy. 2003;58(10):1053-8.
21. Gonzalez-Quintela A, Vidal C, Gude F. Alcohol-induced alterations in serum immunoglobulin e (IgE) levels in human subjects. Frontiers in bioscience : a journal and virtual library. 2002;7:e234-44.
22. Carson CG. Risk factors for developing atopic dermatitis. Danish medical journal. 2013;60(7):B4687.
23. Miles EA, Calder PC. Maternal diet and its influence on the development of allergic disease. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2015;45(1):63-74. doi:10.1111/cea.12453.
24. Kremmyda LS, Vlachava M, Noakes PS, Diaper ND, Miles EA, Calder PC. Atopy risk in infants and children in relation to early exposure to fish, oily fish, or long-chain omega-3 fatty acids: a systematic review. Clinical reviews in allergy & immunology. 2011;41(1):36-66. doi:10.1007/s12016-009-8186-2.
25. Gunaratne AW, Makrides M, Collins CT. Maternal prenatal and/or postnatal n-3 long chain polyunsaturated fatty acids (LCPUFA) supplementation for preventing allergies in early childhood. The Cochrane database of systematic reviews. 2015;7:CD010085. doi:10.1002/14651858.CD010085.pub2.
26. Beckhaus AA, Garcia-Marcos L, Forno E, Pacheco-Gonzalez RM, Celedon JC, Castro-Rodriguez JA. Maternal nutrition during pregnancy and risk of asthma, wheeze and atopic diseases during childhood: a systematic review and meta-analysis. Allergy. 2015. doi:10.1111/all.12729.
27. Kiefte-de Jong JC, Timmermans S, Jaddoe VW, Hofman A, Tiemeier H, Steegers EA et al. High circulating folate and vitamin B-12 concentrations in women during pregnancy are associated with increased prevalence of atopic dermatitis in their offspring. The Journal of nutrition. 2012;142(4):731-8. doi:10.3945/jn.111.154948.
28. Magdelijns FJ, Mommers M, Penders J, Smits L, Thijs C. Folic acid use in pregnancy and the development of atopy, asthma, and lung function in childhood. Pediatrics. 2011;128(1):e135-44. doi:10.1542/peds.2010-1690.
29. Crider KS, Cordero AM, Qi YP, Mulinare J, Dowling NF, Berry RJ. Prenatal folic acid and risk of asthma in children: a systematic review and meta-analysis. The American journal of clinical nutrition. 2013;98(5):1272-81. doi:10.3945/ajcn.113.065623.
30. West CE, Videky DJ, Prescott SL. Role of diet in the development of immune tolerance in the context of allergic disease. Current opinion in pediatrics. 2010;22(5):635-41. doi:10.1097/MOP.0b013e32833d96ef.
31. Kramer MS, Kakuma R. Maternal dietary antigen avoidance during pregnancy or lactation, or both, for preventing or treating atopic disease in the child. Evidence-based child health : a Cochrane review journal. 2014;9(2):447-83. doi:10.1002/ebch.1972.
32. Pali-Schöll I, Herzog R, Wallmann J, Szalai K, Brunner R, Lukschal A et al. Antacids and dietary supplements with an influence on the gastric pH increase the risk for food sensitization. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2010;40(7):1091-8.
33. Pali-Scholl I, Yildirim AO, Ackermann U, Knauer T, Becker C, Garn H et al. Anti-acids lead to immunological and morphological changes in the intestine of BALB/c mice similar to human food allergy. Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie. 2008;60(4-5):337-45. doi:10.1016/j.etp.2008.03.004.
34. Pali-Scholl I, Jensen-Jarolim E. Anti-acid medication as a risk factor for food allergy. Allergy. 2011;66(4):469-77. doi:10.1111/j.1398-9995.2010.02511.x.
35. Riemer AB, Gruber S, Pali-Scholl I, Kinaciyan T, Untersmayr E, Jensen-Jarolim E. Suppression of gastric acid increases the risk of developing immunoglobulin E-mediated drug hypersensitivity: human diclofenac sensitization and a murine sensitization model. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2010;40(3):486-93. doi:10.1111/j.1365-2222.2009.03363.x.
36. Ramirez E, Cabanas R, Laserna LS, Fiandor A, Tong H, Prior N et al. Proton pump inhibitors are associated with hypersensitivity reactions to drugs in hospitalized patients: a nested case-control in a retrospective cohort study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2013;43(3):344-52. doi:10.1111/cea.12034.
37. Trikha A, Baillargeon JG, Kuo YF, Tan A, Pierson K, Sharma G et al. Development of food allergies in patients with gastroesophageal reflux disease treated with gastric acid suppressive medications. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2013;24(6):582-8. doi:10.1111/pai.12103.
38. Scholl I, Ackermann U, Ozdemir C, Blumer N, Dicke T, Sel S et al. Anti-ulcer treatment during pregnancy induces food allergy in mouse mothers and a Th2-bias in their offspring. FASEB journal : official publication of the Federation of American Societies for Experimental Biology. 2007;21(4):1264-70. doi:10.1096/fj.06-7223com.
39. Dehlink E, Yen E, Leichtner AM, Hait EJ, Fiebiger E. First evidence of a possible association between gastric acid suppression during pregnancy and childhood asthma: a population-based register study. Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology. 2009;39(2):246-53. doi:10.1111/j.1365-2222.2008.03125.x.
40. Koplin JJ, Osborne NJ, Wake M, Martin PE, Gurrin LC, Robinson MN et al. Can early introduction of egg prevent egg allergy in infants? A population-based study. The Journal of allergy and clinical immunology. 2010;126(4):807-13. doi:10.1016/j.jaci.2010.07.028.
41. Halvorsen T, Skadberg BT, Eide GE, Roksund OD, Carlsen KH, Bakke P. Pulmonary outcome in adolescents of extreme preterm birth: a regional cohort study. Acta Paediatr. 2004;93(10):1294-300.
42. Schuijs MJ, Willart MA, Vergote K, Gras D, Deswarte K, Ege MJ et al. Farm dust and endotoxin protect against allergy through A20 induction in lung epithelial cells. Science. 2015;349(6252):1106-10. doi:10.1126/science.aac6623.
43. Collin SM, Granell R, Westgarth C, Murray J, Paul ES, Sterne JA et al. Associations of Pet Ownership with Wheezing and Lung Function in Childhood: Findings from a UK Birth Cohort. PloS one. 2015;10(6):e0127756. doi:10.1371/journal.pone.0127756.
44. Lodge CJ, Allen KJ, Lowe AJ, Hill DJ, Hosking CS, Abramson MJ et al. Perinatal cat and dog exposure and the risk of asthma and allergy in the urban environment: a systematic review of longitudinal studies. Clinical & developmental immunology. 2012;2012:176484. doi:10.1155/2012/176484.
45. Pelucchi C, Galeone C, Bach JF, La Vecchia C, Chatenoud L. Pet exposure and risk of atopic dermatitis at the pediatric age: a meta-analysis of birth cohort studies. The Journal of allergy and clinical immunology. 2013;132(3):616-22 e7. doi:10.1016/j.jaci.2013.04.009.
46. Madhok V, Futamura M, Thomas KS, Barbarot S. What's new in atopic eczema? An analysis of systematic reviews published in 2012 and 2013. Part 2. Treatment and prevention. Clinical and experimental dermatology. 2015;40(4):349-54; quiz 54-5. doi:10.1111/ced.12591.
47. Stelmach I, Bobrowska-Korzeniowska M, Smejda K, Majak P, Jerzynska J, Stelmach W et al. Risk factors for the development of atopic dermatitis and early wheeze. Allergy and asthma proceedings : the official journal of regional and state allergy societies. 2014;35(5):382-9. doi:10.2500/aap.2014.35.3786.
48. Jensen-Jarolim E, Pacios L, Bianchini R, Hofstetter G, Roth-Walter F. Structural similarities of human & mammalian lipocalins, and their function in innate immunity and allergy. Allergy. 2015:in press.
49. Jensen-Jarolim E, Pali-Scholl I, Jensen SA, Robibaro B, Kinaciyan T. Caution: Reptile pets shuttle grasshopper allergy and asthma into homes. The World Allergy Organization journal. 2015;8(1):24. doi:10.1186/s40413-015-0072-1.
50. Cuppari C, Manti S, Salpietro A, Alterio T, Arrigo T, Leonardi S et al. Mode of delivery and risk for development of atopic diseases in children. Allergy and asthma proceedings : the official journal of regional and state allergy societies. 2015;36(5):344-51. doi:10.2500/aap.2015.36.3870.
51. Muraro A, Halken S, Arshad SH, Beyer K, Dubois AE, Du Toit G et al. EAACI food allergy and anaphylaxis guidelines. Primary prevention of food allergy. Allergy. 2014;69(5):590-601. doi:10.1111/all.12398.
52. Fleischer DM, Spergel JM, Assa'ad AH, Pongracic JA. Primary prevention of allergic disease through nutritional interventions. The journal of allergy and clinical immunology In practice. 2013;1(1):29-36. doi:10.1016/j.jaip.2012.09.003.
53. Heine RG. Preventing atopy and allergic disease. Nestle Nutrition Institute workshop series. 2014;78:141-53. doi:10.1159/000354954.
54. Stremnitzer C, Manzano-Szalai K, Willensdorfer A, Starkl P, Pieper M, Konig P et al. Papain Degrades Tight Junction Proteins of Human Keratinocytes In Vitro and Sensitizes C57BL/6 Mice via the Skin Independent of its Enzymatic Activity or TLR4 Activation. The Journal of investigative dermatology. 2015;135(7):1790-800. doi:10.1038/jid.2015.58.